ARQT - Arcutis Biotherapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARQT is currently covered by 10 analysts with an average price target of $30.47. This is a potential upside of $15.73 (106.72%) from yesterday's end of day stock price of $14.74.

Arcutis Biotherapeutics 's activity chart (see below) currently has 60 price targets and 83 ratings on display. The stock rating distribution of ARQT is 82.93% BUY and 17.07% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 23.17% with an average time for these price targets to be met of 64.6 days.

Highest price target for ARQT is $22, Lowest price target is $15, average price target is $17.57.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 07-Aug-2025. First documented stock forecast 25-Feb-2020.

Currently out of the existing stock ratings of ARQT, 34 are a BUY (82.93%), 7 are a HOLD (17.07%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$22

$7.88 (55.81%)

$20

5 days ago
(07-Aug-2025)

3/21 (14.29%)

$7.88 (55.81%)

275

Hold

$18

$3.88 (27.48%)

$6

18 days ago
(25-Jul-2025)

1/3 (33.33%)

$3.14 (21.13%)

108

Buy

$19

$4.88 (34.56%)

$19

4 months 9 days ago
(03-Apr-2025)

0/4 (0%)

$2.84 (17.57%)

Buy

4 months 9 days ago
(03-Apr-2025)

1/1 (100%)

$9.67 (36.73%)

27

Hold

$15

$0.88 (6.23%)

$11

5 months 16 days ago
(27-Feb-2025)

3/5 (60%)

$2.2 (17.19%)

41

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARQT (Arcutis Biotherapeutics ) average time for price targets to be met?

On average it took 64.6 days on average for the stock forecasts to be realized with a an average price target met ratio 23.17

Which analyst has the current highest performing score on ARQT (Arcutis Biotherapeutics ) with a proven track record?

GRAIG SUVANNAVEJH

Which analyst has the most public recommendations on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh works at MIZUHO and has 3 price targets and 2 ratings on ARQT

Which analyst is the currently most bullish on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh with highest potential upside - $36.28

Which analyst is the currently most reserved on ARQT (Arcutis Biotherapeutics )?

Nigel Dally with lowest potential downside - -$4.12

Arcutis Biotherapeutics  in the News

Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts

Arcutis Biotherapeutics reported its earnings for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.13, beating the forecast of -$0.17, and reported revenue of $81.5 million, exceeding expectations by 11.26%. This financial performance contributed to a modest after-hours stock price increase of 0.26%,...

Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026

Earnings Call Insights: Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 MANAGEMENT VIEW * Frank Watanabe, President and CEO, reported “strong sales and demand growth with our ZORYVE franchise, demonstrating continued adoption by health care providers and patients and consistent execution by our commercial team.” He highlighted the FDA approval of ZORYVE foam 0.3% for plaque psoriasis...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?